FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wood Gavin					2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
	O ADAPTIMMUNE THERAPEUTICS PLC,				3. Date of Earliest Transaction (Month/Day/Year) 01/17/2023								X Officer (give title Other (specify below) Chief Financial Officer					
OXFORDSHIRE			OX14 4RX		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Tran Date				2. Transa	ction	2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Se Disp		. Secur	ities Acquired d Of (D) (Instr.	(A) or	5. Amount Securities Beneficial Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	V A	Amount (A) or (D)		Price	Transaction (Instr. 3 and				(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transaction Code (Instr. r) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisab Expiration Date (Month/Day/Year)		and	7. Title and A Securities Un Derivative Se 3 and 4)	derlying	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	ly Di or (I)). wnership orm: irect (D) r Indirect ((Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expir Date	ration	Title	Amount or Number of Shares		Transaction (Instr. 4)	on(s)			
Option to purchase Ordinary Shares	\$0.31 ⁽¹⁾	01/17/2023		A		1,407,072		(2)	01/17	7/2033	Ordinary Shares	1,407,072	\$0	1,407,07	72	D		
Option to purchase Ordinary Shares	\$0.0012 ⁽³⁾	01/17/2023		A		314,256		(4)	01/17	7/2033	Ordinary Shares	314,256	\$0	314,250	6	D		
Option to purchase Ordinary Shares	\$0.0012 ⁽⁵⁾	01/17/2023		A		193,728		01/17/2024	01/17	7/2033	Ordinary Shares	193,728	\$0	193,728	8	D		

Explanation of Responses

- 1. The exercise price was converted from GBP0.26 based on an exchange rate of U.S.\$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- 2. Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.
- 3. The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.\$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- 4. Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January 17, 2025 through January 17, 2027.
- 5. The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of \$U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

<u>/s/ Gavin Wood</u> <u>01/17/2023</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.